Discovery of new thymol-3,4-disubstituted thiazole hybrids as dual COX-2/5-LOX inhibitors with in vivo proof

References

• Martel-Pelletier J, Lajeunesse D, Reboul P, Pelletier JP. Therapeutic role of dual inhibitors of 5-lox and cox, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2003;62(6):501–509.
   PubMed Web of Science ®Google Scholar
• Garavito RM, Malkowski MG, DeWitt DL. The structures of prostaglandin endoperoxide h synthases-1 and-2. Prostagland Other Lipid Mediat. 2002;68-69:129–152.
   PubMed Web of Science ®Google Scholar
• Zarghi A, Arfaei S. Selective cox-2 inhibitors: a review of their structure-activity relationships. Iran J Pharm Res. 2011;10(4):655–683.
   PubMed Web of Science ®Google Scholar
• Konturek P, Kania J, Burnat G, Hahn E, Konturek S. Prostaglandins as mediators of cox-2 derived carcinogenesis in gastrointestinal tract. J Physiol Pharmacol. 2005;56(Suppl 5):57–73.
   PubMedGoogle Scholar
• Williams CS, DuBOIS RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol. 1996;270(3 Pt 1):G393–G400.
   PubMed Web of Science ®Google Scholar
• Jouzeau J-Y, Terlain B, Abid A, Nédélec E, Netter P. Cyclo-oxygenase isoenzymes: how recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs. 1997;53(4):563–582.
   PubMed Web of Science ®Google Scholar
• Fu J-Y, Masferrer J, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin h2 synthase (cyclooxygenase) in human monocytes. J Biol Chem. 1990;265(28):16737–16740.
   PubMed Web of Science ®Google Scholar
• Maślińska D, Kaliszek A, Opertowska J, Toborowicz J, Deregowski K, Szukiewicz D. Constitutive expression of cyclooxygenase-2 (cox-2) in developing brain. A. Choroid plexus in human fetuses. Folia Neuropathologica. 1999;37(4):287–291.
   PubMed Web of Science ®Google Scholar
• Kömhoff M, Wang J-L, Cheng H-F, Langenbach R, Mckanna JA, Harris RC, Breyer MD. Cyclooxygenase-2–selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int. 2000;57(2):414–422.
   PubMed Web of Science ®Google Scholar
• Charlier C, Michaux C. Dual inhibition of cyclooxygenase-2 (cox-2) and 5-lipoxygenase (5-lox) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur J Med Chem. 2003;38(7-8):645–659.
   PubMed Web of Science ®Google Scholar
• Young RN. Inhibitors of 5-lipoxygenase: a therapeutic potential yet to be fully realized? Eur J Med Chem. 1999;34(9):671–685.
   Web of Science ®Google Scholar
• Lamie PF, Ali WAM, Bazgier V, Rárová L. Novel n-substituted indole schiff bases as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase enzymes: synthesis, biological activities in vitro and docking study. Eur J Med Chem. 2016;123803–813.
   PubMed Web of Science ®Google Scholar
• Rainsford K. The effects of 5-lipoxygenase inhibitors and leukotriene antagonists on the development of gastric lesions induced by nonsteroidal antiinflammatory drugs in mice. Agents Actions. 1987;21(3-4):316–319.
   PubMedGoogle Scholar
• Rainsford K. Leukotrienes in the pathogenesis of nsaid-induced gastric and intestinal mucosal damage. Agents Actions. 1993;39 Spec No (S1):C24–C26.
   PubMedGoogle Scholar
• Laufer S. Discovery and development of ml3000. Inflammopharmacology. 2001;9(1-2):101–112.
   Google Scholar
• Hudson N, Balsitis M, Everitt S, Hawkey C. Enhanced gastric mucosal leukotriene b4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut. 1993;34(6):742–747.
   PubMed Web of Science ®Google Scholar
• Burnett BP, Levy RM. 5-lipoxygenase metabolic contributions to nsaid-induced organ toxicity. Adv Ther. 2012;29(2):79–98.
   PubMed Web of Science ®Google Scholar
• Sala A, Zarini S, Bolla M. Leukotrienes: lipid bioeffectors of inflammatory reactions. Biochemistry-New York-English Translation of Biokhimiya. 1998;63(1):84–92.
   PubMed Web of Science ®Google Scholar
• Sala A, Zarini S, Bolla M. Leukotrienes: Lipid bioeffectors of inflammatory reactions. Biochemistry (Mosc)). 1998;63(1):84–92.
   PubMed Web of Science ®Google Scholar
• Hallstrand TS, Henderson WR. An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol. 2010;10(1):60–66.
   PubMed Web of Science ®Google Scholar
• Rossi A, Cuzzocrea S, Sautebin L. Involvement of leukotriene pathway in the pathogenesis of ischemia-reperfusion injury and septic and non-septic shock. Curr Vasc Pharmacol. 2009;7(2):185–197.
   PubMed Web of Science ®Google Scholar
• Wang D, DuBois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10(3):181–193.
   PubMed Web of Science ®Google Scholar
• Bäck M. Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc Drugs Ther. 2009;23(1):41–48.
   PubMed Web of Science ®Google Scholar
• Yoshimura H, Sekine S, Adachi H, Uematsu Y, Mitani A, Futaki N, Shimizu N. High levels of human recombinant cyclooxygenase-1 expression in mammalian cells using a novel gene amplification method. Protein Expr Purif. 2011;80(1):41–46.
   PubMed Web of Science ®Google Scholar
• Yao B, Xu J, Harris RC, Zhang M-Z. Renal localization and regulation of 15-hydroxyprostaglandin dehydrogenase. Am J Physiol Renal Physiol. 2008;294(2):433–439.
   Web of Science ®Google Scholar
• Haruna H, Shimizu T, Ohtsuka Y, Yarita Y, Fujii T, Kudo T, Yamashiro Y. Expression of cox-1, cox-2, and ppar-γ in the gastric mucosa of children with helicobacter pylori infection. Pediatr Int. 2008;50(1):1–6.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Ujiki M, Ding X-Z, Pelham C, Talamonti MS, Bell RH, Denham W, Adrian TE. Pancreatic stellate cells (pscs) express cyclooxygenase-2 (cox-2) and pancreatic cancer stimulates cox-2 in pscs. Mol Cancer. 2005;4(1):27.
   PubMedGoogle Scholar
• Abdelall EKA, Kamel GM. Synthesis of new thiazolo-celecoxib analogues as dual cyclooxygenase-2/15-lipoxygenase inhibitors: determination of regio-specific different pyrazole cyclization by 2d nmr. Eur J Med Chem. 2016;118(:250–258.
   PubMed Web of Science ®Google Scholar
• Garcia-Rodriguez LA, Hernández-Diaz S. Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology. 2003;14:240–246.
   PubMed Web of Science ®Google Scholar
• Ruan CH, So SP, Ruan KH. Inducible cox-2 dominates over cox-1 in prostacyclin biosynthesis: Mechanisms of cox-2 inhibitor risk to heart disease. Life Sci. 2011;88(1-2):24–30.
   PubMed Web of Science ®Google Scholar
• Khan M, Fraser A. Cox-2 inhibitors and the risk of cardiovascular thrombotic events. Ir Med J. 2012;105(4):119–121.
   PubMedGoogle Scholar
• Singh P, Prasher P, Dhillon P, Bhatti R. Indole based peptidomimetics as anti-inflammatory and anti-hyperalgesic agents: Dual inhibition of 5-lox and cox-2 enzymes. Eur J Med Chem. 2015;97:104–123.
   PubMed Web of Science ®Google Scholar
• Tries S, Neupert W, Laufer S. The mechanism of action of the new antiinflammatory compound ml3000: Inhibition of 5-lox and cox-1/2. Inflamm Res. 2002;51(3):135–143.
   PubMed Web of Science ®Google Scholar
• Alvaro-Gracia JM. Licofelone—clinical update on a novel lox/cox inhibitor for the treatment of osteoarthritis. Rheumatology (Oxford)). 2004;43 Suppl 1 (90001):i21–i25.
   PubMedGoogle Scholar
• Philoppes JN, Abdelgawad MA, Abourehab MAS, Sebak M,A, Darwish M, Lamie PF. Novel n-methylsulfonyl-indole derivatives: biological activity and cox-2/5-lox inhibitory effect with improved gastro protective profile and reduced cardio vascular risks. J Enzyme Inhib Med Chem. 2023;38(1):246–266.
   PubMed Web of Science ®Google Scholar
• Botelho MA, Barros G, Queiroz DB, Carvalho CF, Gouvea J, Patrus L, Bannet M, Patrus D, Rego A, Silva I, et al. Nanotechnology in phytotherapy: antiinflammatory effect of a nanostructured thymol gel from lippia sidoides in acute periodontitis in rats. Phytother Res. 2016;30(1):152–159.
   PubMed Web of Science ®Google Scholar
• Marsik P, Kokoska L, Landa P, Nepovim A, Soudek P, Vanek T. In vitro inhibitory effects of thymol and quinones of nigella sativa seeds on cyclooxygenase-1- and -2-catalyzed prostaglandin e2 biosyntheses. Planta Med. 2005;71(8):739–742.
   PubMed Web of Science ®Google Scholar
• Meeran N, Fizur M, Javed H, Al Taee H, Azimullah S, Ojha SK. Pharmacological properties and molecular mechanisms of thymol: Prospects for its therapeutic potential and pharmaceutical development. Front Pharmacol. 2017;8(:380.
   PubMed Web of Science ®Google Scholar
• Tsai M-L, Lin C-C, Lin W-C, Yang C-H. Antimicrobial, antioxidant, and anti-inflammatory activities of essential oils from five selected herbs. Biosci Biotechnol Biochem. 2011;75(10):1977–1983.
   PubMed Web of Science ®Google Scholar
• El-Miligy MMM, Al-Kubeisi AK, Bekhit MG, El-Zemity SR, Nassra RA, Hazzaa AA. Towards safer anti-inflammatory therapy: Synthesis of new thymol–pyrazole hybrids as dual cox-2/5-lox inhibitors. J Enzyme Inhib Med Chem. 2023;38(1):294–308.
   PubMed Web of Science ®Google Scholar
• El-Miligy MMM, Al-Kubeisi AK, El-Zemity SR, Nassra RA, Abu-Serie MM, Hazzaa AA. Discovery of small molecule acting as multitarget inhibitor of colorectal cancer by simultaneous blocking of the key cox-2, 5-lox and pim-1 kinase enzymes. Bioorg Chem. 2021;115:105171.
   PubMed Web of Science ®Google Scholar
• Che X-H, Chen C-L, Ye X-L, Weng G-B, Guo X-Z, Yu W-Y, Tao J, Chen Y-C, Chen X. Dual inhibition of cox-2/5-lox blocks colon cancer proliferation, migration and invasion in vitro. Oncol Rep. 2016;35(3):1680–1688.
   PubMed Web of Science ®Google Scholar
• Sinha S, Sravanthi T, Yuvaraj S, Manju S, Doble M. 2-amino-4-aryl thiazole: a promising scaffold identified as a potent 5-lox inhibitor. RSC Adv. 2016;6(23):19271–19279.
   Web of Science ®Google Scholar
• Apostolidis I, Liaras K, Geronikaki A, Hadjipavlou-Litina D, Gavalas A, Soković M, Glamočlija J, Ćirić A. Synthesis and biological evaluation of some 5-arylidene-2-(1, 3-thiazol-2-ylimino)-1, 3-thiazolidin-4-ones as dual anti-inflammatory/antimicrobial agents. Bioorg Med Chem. 2013;21(2):532–539.
   PubMed Web of Science ®Google Scholar
• Jacob P J, Manju SL. Identification and development of thiazole leads as cox-2/5-lox inhibitors through in-vitro and in-vivo biological evaluation for anti-inflammatory activity. Bioorg Chem. 2020;100(:103882.
   PubMed Web of Science ®Google Scholar
• P JJ, S L M. Novel approach of multi-targeted thiazoles and thiazolidenes toward anti-inflammatory and anticancer therapy—dual inhibition of cox-2 and 5-lox enzymes. Med Chem Res. 2021;30(1):236–257.
   Web of Science ®Google Scholar
• Rajput J, Bagul S, Tadavi S, Karandikar P, Bendre R. Design, synthesis and biological evaluation of novel class diindolyl methanes (dims) derived from naturally occurring phenolic monoterpenoids. Med Chem. 2016;6(2):123–128.
   Google Scholar
• Duff JC. 96. A new general method for the preparation of o-hydroxyaldehydes from phenols and hexamethylenetetramine. J Chem Soc. 1941:547–550.
   Google Scholar
• Casiraghi G, Casnati G, Cornia M, Pochini A, Puglia G, Sartori G, Ungaro R. Selective reactions using metal phenoxides. Part 1. Reactions with formaldehyde. J Chem Soc, Perkin Trans 1. 1978;4(4):318–321.):
   Google Scholar
• Casnati G, Casiraghi G, Puglia G, Sartori G, Terenghi G. Process for preparing 2-hydroxybenzoic aldehydes. In. Process for preparing 2-hydroxybenzoic aldehydes: Google Patents; 1979.
   Google Scholar
• Yousef TA, Badria FA, Ghazy SE, El-Gammal OA, El-Reash GMA. In vitro and in vivo antitumor activity of some synthesized 4-(2-pyridyl)-3-thiosemicarbazides derivatives. Int J Med Med Sci. 2011;3(2):37–46.
   Google Scholar
• Serra S, Moineaux L, Vancraeynest C, Masereel B, Wouters J, Pochet L, Frédérick R. Thiosemicarbazide, a fragment with promising indolamine-2, 3-dioxygenase (ido) inhibition properties. Eur J Med Chem. 2014;82(:96–105.
   PubMed Web of Science ®Google Scholar
• Betz R, McCleland C, Marchand H. 2-bromo-1-phenylethanone. Acta Crystallogr Sect E Struct Rep Online. 2011;67(Pt 5):o1207–o1207.
   PubMedGoogle Scholar
• Tada N, Ban K, Hirashima S-i, Miura T, Itoh A. Direct synthesis of α-bromoketones from alkylarenes by aerobic visible light photooxidation. Org Biomol Chem. 2010;8(20):4701–4704.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhuang L-h, Wang G-w. 2-bromo-1-(4-methoxyphenyl) ethanone. Acta Crystallogr Sect E Struct Rep Online. 2009;65(Pt 9):o2245.
   PubMedGoogle Scholar
• Cox inhibitor screening assay kit. No. 560131.
   Google Scholar
• Cayman C. Lipoxygenase inhibitor screening assay kit 760700..
   Google Scholar
• Razmi A, Zarghi A, Arfaee S, Naderi N, Faizi M. Evaluation of anti-nociceptive and anti-inflammatory activities of novel chalcone derivatives. Iran J Pharm Res. 2013;12(Suppl):153–159.
   PubMedGoogle Scholar
• Lakshmi V, Mishra V, Palit G. A new gastroprotective effect of limonoid compounds xyloccensins x and y from xylocarpus molluccensis in rats. Nat Prod Bioprospect. 2014;4(5):277–283.
   PubMedGoogle Scholar
• Hazzaa AA-E. Synthesis and biological evaluation of novel terpene derivatives. AlexU-IACUC (Member of ICLAS) 2019.
   Google Scholar
• Srivastava S, Nath C, Gupta M, Vrat S, Sinha J, Dhawan K, Gupta G. Protection against gastric ulcer by verapamil. Pharmacol Res. 1991;23(1):81–86.
   PubMed Web of Science ®Google Scholar
• Molecular operating environment (moe) 2016.08, chemical computing group inc. 1010 sherbrooke st. West, suite #910, montreal, qc, canada, h3a2r7. www.Chemcomp.Com.
   Google Scholar
• Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, Lindahl E. Gromacs: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1-2:19–25.
   Google Scholar
• https://simlab.Uams.Edu/.
   Google Scholar
• Bullock AN, Russo S, Amos A, Pagano N, Bregman H, Debreczeni JE, Lee WH, von Delft F, Meggers E, Knapp S. Crystal structure of the pim2 kinase in complex with an organoruthenium inhibitor. Plos One. 2009;4(10):e7112.
   PubMed Web of Science ®Google Scholar
• Sotriffer Accounting AC. for induced-fit effects in docking: What is possible and what is not? Curr Top Med Chem. 2011;11(2):179–191.
   PubMed Web of Science ®Google Scholar
• Barreca ML, Iraci N, De Luca L, Chimirri A. Induced‐fit docking approach provides insight into the binding mode and mechanism of action of hiv‐1 integrase inhibitors. ChemMedChem Chem Enabl Drug Discov. 2009;4(9):1446–1456.
   PubMed Web of Science ®Google Scholar
• Wang JL, Limburg D, Graneto MJ, Springer J, Hamper JRB, Liao S, Pawlitz JL, Kurumbail RG, Maziasz T, Talley JJ, et al. The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: The second clinical candidate having a shorter and favorable human half-life. Bioorg Med Chem Lett. 2010;20(23):7159–7163.
   PubMed Web of Science ®Google Scholar
• Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996;384(6610):644–648.
   PubMed Web of Science ®Google Scholar
• Gilbert NC, Rui Z, Neau DB, Waight MT, Bartlett SG, Boeglin WE, Brash AR, Newcomer ME. Conversion of human 5-lipoxygenase to a 15-lipoxygenase by a point mutation to mimic phosphorylation at serine-663. Faseb J. 2012;26(8):3222–3229.
   PubMed Web of Science ®Google Scholar
• Hsu K-C, HuangFu W-C, Lin TE, Chao M-W, Sung T-Y, Chen Y-Y, Pan S-L, Lee J-C, Tzou S-C, Sun C-M, et al. A site-moiety map and virtual screening approach for discovery of novel 5-lox inhibitors. Sci Rep. 2020;10(1):10510.
   PubMed Web of Science ®Google Scholar